A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893)

Autor: Willemze, R., Suciu, S., Archimbaud, E., Muus, P., Stryckmans, P., Louwagie, E.A., Berneman, Z., Tjean, M., Wijermans, P., Dohner, H., Jehn, U., Labar, Boris, Jakšić, Branimir, Dardenne, M., Zittoun, R.
Rok vydání: 1997
Předmět:
azacytidine
randomized trial
relapsed leukemia
The activity of Idarubicin in relation to multidrug resistance expression and proliferation in subpopulations of hematopoietic progenitor cells in normal and leukemic bone marrow
De activiteit van Idarubicine in relatie tot "multiple drug resistance" (MDR)-expressie en proliferatie in subpopulaties van hematopoietische progenitorcellen in normaal en leukemisch beenme
Zdroj: Leukemia, 11, S24-S27
Leukemia, 11, 1, pp. S24-S27
ISSN: 0887-6924
Popis: 5-Aza-2"-deoxycytidine combined with either amsacrine or idarubicin has been applied in a treatment protocol for patients with a relapse of acute myeloid or lymphocytic leukemia. Sixty-three patients received 5-Aza-2"-deoxycytidine 125 mg/m2 as a 6 h infusion every 12 h for 6 days in combination with either amsacrine 120 mg/m2 as a 1 h infusion on days 6 and 7 (n=30) or idarubicin 12 mg/m2 as a 15 min infusion on days 5, 6 and 7 (n = 33). Twenty-three patients (36.5%) obtained a complete remission (CR) ; eight of 30 patients treated with amsacrine and 15 of 33 treated with idarubicin. Patients with an interval of more than 1 year between initial diagnosis and start of the protocol achieved CR in 51.4%, compared to 15.4% for patients with an interval of less than 1 year. Patients with normal cytogenetics had a higher CR rate (61%) than those with abnormal cytogenetic findings (15.8%). Digestive tract and hematologic toxicity was prolonged, compared to standard induction schedules. Median disease-free survival was approximately 8 months, with only 20% of patients staying in remission for more than 1 year. 5-Aza-2"-deoxycytidine is a good antileukemic agent with considerable toxicity. Current results merit further investigations in previously untreated leukemia.
Databáze: OpenAIRE
Externí odkaz: